Literature DB >> 31646571

MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition.

Y-W Xuan1, M Liao, W-L Zhai, L-J Peng, Y Tang.   

Abstract

OBJECTIVE: To investigate the role of miR-381 in the progression of lung adenocarcinoma (LA) and its underlying mechanism. PATIENTS AND METHODS: A total of 54 pairs of LA tissues and para-carcinoma tissues were obtained from May 2015 to April 2017 in our hospital. Four human LA cell lines (A549, SPC-A1, H1299, and PC-9) and one normal human pulmonary epithelial cell line BEAS-2B were obtained and cultured. The protein and mRNA expression levels were detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) and Western blot, respectively. Additionally, cell proliferation assays and cell migration and invasion assays were used. Furthermore, tumor xenograft model in nude mice was made in this study.
RESULTS: miR-381 was notably downregulated in LA tissues. Moreover, low miR-381 expression was confirmed to be strongly correlated with poor prognosis and aggressive clinicopathological characteristics of LA patients. Exogenous miR-381 overexpression was found to notably restrict LA cell proliferation, migration, and invasion; additionally, miR-381 overexpression could significantly reduce tumor growth in vivo. Mechanistically, LMO3 was determined as a novel direct target for miR-381 in LA cells. In clinical LA tissues, the LMO3 expressions were clearly overexpressed. Furthermore, miR-381 overexpression affected the PI3K/Akt pathway and EMT in LA.
CONCLUSIONS: MiR-381 played key roles in LA progression, partially via directly targeting LMO3 and regulating the PI3K/Akt signaling pathway and EMT. Thus, the miR-381/ LMO3 axis has clinical significance in the therapy of patients with LA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31646571     DOI: 10.26355/eurrev_201910_19152

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Sirt1 inhibits renal tubular cell epithelial-mesenchymal transition through YY1 deacetylation in diabetic nephropathy.

Authors:  Lei Du; Xuan Qian; Yuan Li; Xi-Zhi Li; Lin-Lin He; Liu Xu; Yi-Qi Liu; Cheng-Cheng Li; Pu Ma; Fang-Lin Shu; Qian Lu; Xiao-Xing Yin
Journal:  Acta Pharmacol Sin       Date:  2020-06-17       Impact factor: 6.150

Review 2.  MicroRNA-381-A Key Transcriptional Regulator: Its Biological Function and Clinical Application Prospects in Cancer.

Authors:  Xue Zeng; Zhe Cao; Wenhao Luo; Lianfang Zheng; Taiping Zhang
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

Review 3.  MicroRNA-381 in human cancer: Its involvement in tumour biology and clinical applications potential.

Authors:  Huanhuan Sha; Yujie Gan; Feng Xu; Yue Zhu; Renrui Zou; Weiwei Peng; Zhiya Wu; Rong Ma; Jianzhong Wu; Jifeng Feng
Journal:  J Cell Mol Med       Date:  2022-01-11       Impact factor: 5.310

4.  Bioinformatics Profiling and Experimental Validation of 4 Differentially-Expressed LIM Genes in the Course of Colorectal-Adenoma-Carcinoma.

Authors:  Ying He; Zongfu Pan; Qian Shi; Xilin Zhang; Weiyun Shen; Lixia Huo; Huihui Guo; Chengwu Tang; Yuhang Ling
Journal:  Med Sci Monit       Date:  2022-07-20

Review 5.  MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands.

Authors:  Daniel G Henriques; Elisa B Lamback; Romulo S Dezonne; Leandro Kasuki; Monica R Gadelha
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

6.  Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis.

Authors:  Dan Jin; Jiwei Guo; Yan Wu; Weiwei Chen; Jing Du; Lijuan Yang; Xiaohong Wang; Kaikai Gong; Juanjuan Dai; Shuang Miao; Xuelin Li; Guoming Su
Journal:  J Exp Clin Cancer Res       Date:  2020-01-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.